RedHill Biopharma Ltd.

NASDAQ (USD): RedHill Biopharma Ltd. (RDHL)

Last Price

0.537

Today's Change

-0.001 (0.18%)

Day's Change

0.51 - 0.546

Trading Volume

599,752

Overview

Market Cap

15 Million

Shares Outstanding

29 Million

Avg Volume

10,021,327

Avg Price (50 Days)

0.96

Avg Price (200 Days)

1.11

PE Ratio

-0.07

EPS

-8.00

Earnings Announcement

21-Feb-2024

Previous Close

0.54

Open

0.54

Day's Range

0.51 - 0.5459

Year Range

0.257 - 9.76

Trading Volume

600,872

Price Change Highlight

1 Day Change

-0.19%

5 Day Change

-2.43%

1 Month Change

-17.27%

3 Month Change

70.33%

6 Month Change

-40.95%

Ytd Change

-63.19%

1 Year Change

-94.03%

3 Year Change

-99.86%

5 Year Change

-99.83%

10 Year Change

-99.90%

Max Change

-99.88%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Description:

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment